These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
37-1744899
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
1450 Centrepark Boulevard, Suite 210
West Palm Beach, Florida
|
33401
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Large accelerated filer
ý
|
Accelerated filer
¨
|
Non-Accelerated filer
¨
|
Smaller reporting company
¨
|
|
Class
|
May 6, 2016
|
|
Common Stock, par value $0.01 per share
|
229,557,867 shares
|
|
|
Page
|
|
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
Terms
|
|
Definitions
|
|
Platform; We; Us; Our; the Company
|
|
Platform Specialty Products Corporation, a Delaware corporation, and its subsidiaries, collectively, for all periods subsequent to the MacDermid Acquisition.
|
|
Acquisitions
|
|
Agriphar Acquisition, Alent Acquisition, Arysta Acquisition, CAS Acquisition, MacDermid Acquisition, OMG Acquisition and OMG Malaysia Acquisition, collectively.
|
|
Agriphar
|
|
Percival and its agrochemical business, Agriphar.
|
|
Agriphar Acquisition
|
|
Acquisition of a 100% interest in Agriphar, completed on October 1, 2014.
|
|
AIs
|
|
Active ingredients.
|
|
Alent
|
|
Alent plc (LSE:ALNT), a formerly public limited company registered in England and Wales.
|
|
Alent Acquisition
|
|
Acquisition of a 100% interest in Alent completed on December 1, 2015 under the U.K. Companies Act.
|
|
Alent EURO Tranche C-2 Term Loan
|
|
Tranche C-2 term loans denominated in Euros in an aggregate amount of €300 million borrowed by Platform in connection with the Alent Acquisition.
|
|
Alent U.S. Dollar Tranche B-3 Term Loan
|
|
Tranche B-3 term loans denominated in U.S. Dollars in an aggregate principal amount of $1.05 billion, borrowed by Platform in connection with the Alent Acquisition.
|
|
Amended and Restated Credit Agreement
|
|
Platform’s credit agreement dated April 12, 2007, as amended and/or restated on June 7, 2013, October 31, 2013 (Amendment No. 1), August 6, 2014 (Second Amended and Restated Credit Agreement and the further amendments pursuant to Amendment No. 2), October 1, 2014 (Incremental Amendment No. 1), February 13, 2015 (Amendment No. 3) and December 3, 2015 (Amendment No.4).
|
|
Amendment No. 1
|
|
Amendment No. 1, dated as of October 31, 2013, among, inter alia, Platform (formerly Platform Acquisition Holding Limited), MacDermid Holdings, Matrix Acquisition Corp., MacDermid (as successor to Matrix Acquisition Corp., the borrower), the subsidiaries of the borrower from time to time parties thereto, the lenders from time to time parties thereto and Credit Suisse AG, as administrative agent and as collateral agent, entered into in connection with the MacDermid Acquisition.
|
|
Amendment No. 2
|
|
Amendment No. 2, dated as of August 6, 2014, among Platform, MacDermid Holdings, MacDermid, the subsidiaries of Platform and MacDermid Holdings from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent, entered into in connection with the CAS Acquisition, including the further amendments to the Second Amended and Restated Credit Agreement which became effective upon closing of the CAS acquisition (see Note 8. Debt, Capital Leases, Financial Guarantees and Factoring Arrangements, to the Consolidated Financial Statements).
|
|
Amendment No. 3
|
|
Amendment No. 3, dated as of February 13, 2015,among Platform, MacDermid Holdings, MAS Holdings, NAIP and certain subsidiaries of Platform and MacDermid Holdings, the lenders from time to time parties thereto and Barclays Bank PLC, entered into in connection with the Arysta Acquisition.
|
|
Amendment No. 4
|
|
Amendment No. 4, dated as of December 3, 2015, among Platform, MacDermid, MAS Holdings, NAIP, MacDermid Europe and MacDermid Funding, the subsidiaries of Platform from time to time parties thereto, the lenders from time to time parties thereto, and Barclays Bank PLC, as administrative agent and collateral agent, entered into in connection with the Alent Acquisition.
|
|
Annual Report
|
|
Platform's annual report on Form 10-K for the fiscal year ended December 31, 2015, filed with the SEC on March 11, 2016.
|
|
Arysta
|
|
Arysta LifeScience Limited, a formerly Irish private limited company.
|
|
Arysta Acquisition
|
|
Acquisition of a 100% interest in Arysta, completed on February 13, 2015.
|
|
Arysta EURO Tranche C-1 Term Loan
|
|
Tranche C-1 term loans denominated in Euros in an aggregate amount of €83 million borrowed by Platform in connection with the Arysta Acquisition.
|
|
Arysta Seller
|
|
Nalozo, L.P., an affiliate of the Original Arysta Seller who became the seller in the Arysta Acquisition pursuant to an amendment to the share purchase agreement dated February 11, 2015.
|
|
Arysta U.S. Dollar Tranche B-2 Term Loan
|
|
Tranche B-2 term loans denominated in U.S. Dollars in an aggregate principal amount of $500 million borrowed by Platform in connection with the Arysta Acquisition.
|
|
ASU
|
|
Accounting Standards Update.
|
|
Asset-Lite, High-Touch
|
|
Platform’s philosophy and business model focused on dedicating extensive resources to research and development and highly technical customer service teams, while limiting investments in fixed assets and capital expenditures.
|
|
Terms
|
|
Definitions
|
|
Board
|
|
Platform’s board of directors.
|
|
CAS
|
|
The Chemtura AgroSolutions business of Chemtura.
|
|
CAS Acquisition
|
|
Acquisition of a 100% interest in CAS, completed on November 3, 2014.
|
|
CAS EURO Tranche C-1 Term Loan
|
|
Tranche C-1 term loans denominated in Euros in an aggregate amount of €205 million borrowed by Platform in connection with the CAS Acquisition.
|
|
CAS U.S. Dollar Tranche B Term Loan
|
|
Tranche B term loans denominated in U.S. Dollars in an aggregate principal amount of $130 million borrowed by Platform in connection with the CAS Acquisition.
|
|
Chemtura
|
|
Chemtura Corporation, a Delaware corporation.
|
|
Credit Facilities
|
|
The First Lien Credit Facility and the Revolving Credit Facility, collectively, available under the Amended and Restated Credit Agreement.
|
|
Domestic Pension Plan
|
|
MacDermid, Incorporated Employees’ Pension Plan (as amended and restated, effective January 1, 2009), a non-contributory domestic defined benefit pension plan.
|
|
EBITDA
|
|
Earnings before interest, taxes, depreciation and amortization.
|
|
ESPP
|
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan, adopted by the Board on March 6, 2014 and approved by Platform’s stockholders at the annual meeting held on June 12, 2014.
|
|
Exchange Act
|
|
Securities Exchange Act of 1934, as amended.
|
|
Exchange Agreement
|
|
Exchange Agreement, dated October 25, 2013, between Platform and the fiduciaries of the MacDermid, Incorporated Profit Sharing and Employee Savings Plan.
|
|
FASB
|
|
Financial Accounting Standard Board.
|
|
FCPA
|
|
Foreign Corrupt Practices Act of 1977.
|
|
February 2015 Notes Offering
|
|
Private offering of $1.10 billion aggregate principal amount of 6.50% USD Notes due 2022 and €350 million aggregate principal amount of 6.00% EUR Notes due 2023, completed on February 2, 2015.
|
|
First Lien Credit Facility
|
|
First lien credit facility available under the Amended and Restated Credit Agreement.
|
|
Founder Entities
|
|
Mariposa Acquisition, LLC and Berggruen Holdings Ltd. and its affiliates, collectively.
|
|
GBP
|
|
Platform's Global BioSolutions Portfolio within its Agricultural Solutions segment, which includes biostimulants, innovative nutrition and biocontrol products.
|
|
GVAP
|
|
Platform’s Global Value Added Portfolio within its Agricultural Solutions segment, which includes products in the herbicides, insecticides, fungicides and seed treatment categories, based on patented or proprietary off-patent AIs.
|
|
Incremental Amendment No. 1
|
|
Incremental amendment No. 1 to the Amended and Restated Credit Agreement, dated as of October 1, 2014, by and among Platform and MacDermid, as borrowers, MacDermid Holdings, certain subsidiaries of MacDermid Holdings and Platform, Barclays Bank PLC, as collateral agent and administrative agent, and the incremental lender party thereto, entered into in connection with the Agriphar Acquisition.
|
|
June 2015 Equity Offering
|
|
Underwritten public offering of 18,226,414 shares of its common stock at a public offering price of $26.50 per share, which closed on June 29, 2015, raising gross proceeds of approximately $483 million.
|
|
LTCB
|
|
Platform's Long Term Cash Bonus plan, established in March 2015.
|
|
MacDermid
|
|
MacDermid, Incorporated, a Connecticut corporation.
|
|
MacDermid Acquisition
|
|
Platform’s acquisition on October 31, 2013 of substantially all of the equity of MacDermid Holdings, which, at the time, owned approximately 97% of MacDermid. As a result, Platform became a holding company for the MacDermid business. Platform acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of the Exchange Agreement.
|
|
MacDermid Europe
|
|
MacDermid European Holdings, B.V., a company organized under the laws of the Netherlands and a subsidiary of Platform.
|
|
MacDermid Funding
|
|
MacDermid Funding LLC, a limited liability company organized under the laws of Delaware and a subsidiary of Platform.
|
|
MacDermid Holdings
|
|
MacDermid Holdings, LLC which, at the time of the MacDermid Acquisition, owned approximately 97% of MacDermid, a subsidiary of MacDermid Holdings.
|
|
MAS Holdings
|
|
MacDermid Agricultural Solutions Holdings B.V., a company organized under the laws of the Netherlands and a subsidiary of Platform.
|
|
NAV
|
|
Net asset value.
|
|
Terms
|
|
Definitions
|
|
NAIP
|
|
Netherlands Agricultural Investment Partners, LLC, a company organized under the laws of Delaware and a subsidiary of Platform.
|
|
NYSE
|
|
New York Stock Exchange.
|
|
November 2015 Notes Offering
|
|
Private offering of $500 million aggregate principal amount of 10.375% senior notes due 2021, completed on November 10, 2015.
|
|
OMG
|
|
OM Group, Inc. (NYSE:OMG), a Delaware corporation.
|
|
OMG Businesses
|
|
OMG's Electronic Chemicals and Photomasks businesses, collectively, other than OMG Malaysia.
|
|
OMG Malaysia
|
|
OMG Electronic Chemicals (M) Sdn Bhd, a subsidiary of OMG located in Malaysia, acquired separately by Platform in the OMG Malaysia Acquisition.
|
|
OMG Acquisition
|
|
Platform's acquisition of 100% interest in the OMG Businesses completed on October 28, 2015.
|
|
OMG Malaysia Acquisition
|
|
Platform's acquisition of 100% interest in OMG Malaysia completed on January 31, 2016.
|
|
Original Arysta Seller
|
|
Nalozo S.à.r.l., a Luxembourg limited liability company and the original seller in the Arysta Acquisition.
|
|
PDH
|
|
Platform Delaware Holdings, Inc., a subsidiary of Platform.
|
|
PDH Common Stock
|
|
Shares of common stock of PDH.
|
|
Pension Plan
|
|
MacDermid, Incorporated Employees’ Pension Plan (as amended and restated, effective January 1, 2009), a non-contributory domestic defined benefit pension plan.
|
|
Percival
|
|
Percival S.A., a société anonyme incorporated and organized under the laws of Belgium, acquired by Platform on October 1, 2014.
|
|
Quarterly Report
|
|
This quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2016.
|
|
Retaining Holder
|
|
Each Holder of an equity interest of MacDermid Holdings immediately prior to the closing of the MacDermid Acquisition, not owned by Platform, who executed a RHSA.
|
|
Revolving Credit Facility
|
|
Revolving Credit Facility (in U.S. Dollars or multicurrency) available under the Amended and Restated Credit Agreement.
|
|
RHSA
|
|
Retaining Holder Securityholders’ Agreement dated as of October 31, 2013 entered into by and between Platform and each Retaining Holder pursuant to which they agreed to exchange their respective interests in MacDermid Holdings for shares of PDH Common Stock, at an exchange rate of $11.00 per share plus (i) a proportionate share of the $100 million contingent consideration and (ii) an interest in certain MacDermid pending litigation.
|
|
RSUs
|
|
Restricted stock units issued by Platform from time to time under the 2013 Plan.
|
|
SEC
|
|
Securities and Exchange Commission.
|
|
Security Agreement
|
|
Amended and Restated Pledge and Security Agreement, amended and restated as of October 31, 2013, as amended, supplemented and modified from time to time, entered into by Platform, MacDermid and the guarantors listed therein.
|
|
Second Amended and Restated Credit Agreement
|
|
Second Amended and Restated Credit Agreement, dated as of August 6, 2014, among, inter alia, Platform, MacDermid Holdings, MacDermid, the subsidiaries of Platform and MacDermid Holdings from time to time parties thereto, the lenders from time to time parties thereto and Barclays Bank PLC, as administrative agent and collateral agent.
|
|
Senior Notes
|
|
Our 6.00% EUR Notes due 2023, 6.50% USD Notes due 2022 and 10.375% USD Notes due 2021, collectively.
|
|
Series A Preferred Stock
|
|
2,000,000 shares of Platform’s Series A convertible preferred stock which were automatically converted from ordinary shares held by the Founder Entities upon the Domestication, and which are convertible into shares of Platform’s common stock, on a one-for-one basis, at any time at the option of the Founder Entities.
|
|
Series B Convertible Preferred Stock
|
|
600,000 shares of Platform’s Series B convertible preferred stock issued to the Arysta Seller in connection with the Arysta Acquisition on February 13, 2015, which are convertible into a maximum of 22,107,590 shares of Platform's common stock at the option of the Arysta Seller.
|
|
SERP
|
|
Supplemental Executive Retirement Plan for executive officers of Platform.
|
|
U.K. Companies Act
|
|
The U.K. Companies Act 2006, as amended.
|
|
USD Incremental Loan
|
|
Incremental term loans under the Incremental Amendment No. 1 to the Amended and Restated Credit Agreement in an aggregate principal amount of $300 million used to finance the Agriphar Acquisition.
|
|
U.S. GAAP
|
|
Generally accepted accounting principles in the United States.
|
|
Terms
|
|
Definitions
|
|
2013 Plan
|
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan adopted by the Board on October 31, 2013, as amended on December 16, 2013 and approved by Platform’s stockholders at the annual meeting held on June 12, 2014.
|
|
401K Plan
|
|
MacDermid, Incorporated Profit Sharing and Employee Savings Plan.
|
|
6.00% EUR Notes due 2023
|
|
Platform’s 6.00% senior notes due 2023 denominated in Euros issued in the February 2015 Notes Offering.
|
|
6.50% USD Notes due 2022
|
|
Platform’s 6.50% senior notes due 2022 denominated in U.S. Dollars issued in the February 2015 Notes Offering.
|
|
10.375% USD Notes due 2021
|
|
Platform's 10.375% senior notes due 2021 denominated in U.S. Dollars issued in the November 2015 Notes Offering.
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2016
|
|
2015
|
||||
|
Net sales
|
$
|
823.8
|
|
|
$
|
534.8
|
|
|
Cost of sales
|
467.8
|
|
|
327.7
|
|
||
|
Gross profit
|
356.0
|
|
|
207.1
|
|
||
|
Operating expenses:
|
|
|
|
|
|||
|
Selling, technical, general and administrative
|
284.0
|
|
|
192.0
|
|
||
|
Research and development
|
19.9
|
|
|
12.9
|
|
||
|
Total operating expenses
|
303.9
|
|
|
204.9
|
|
||
|
Operating profit
|
52.1
|
|
|
2.2
|
|
||
|
Other (expense) income:
|
|
|
|
|
|
||
|
Interest expense, net
|
(93.8
|
)
|
|
(39.4
|
)
|
||
|
Loss on derivative contracts
|
(5.3
|
)
|
|
—
|
|
||
|
Foreign exchange (loss) gain
|
(71.1
|
)
|
|
33.9
|
|
||
|
Other income, net
|
2.1
|
|
|
1.7
|
|
||
|
Total other expense
|
(168.1
|
)
|
|
(3.8
|
)
|
||
|
Loss before income taxes and non-controlling interests
|
(116.0
|
)
|
|
(1.6
|
)
|
||
|
Income tax expense
|
(18.4
|
)
|
|
(24.7
|
)
|
||
|
Net loss
|
(134.4
|
)
|
|
(26.3
|
)
|
||
|
Net income attributable to the non-controlling interests
|
(0.4
|
)
|
|
(0.4
|
)
|
||
|
Net loss attributable to common stockholders
|
$
|
(134.8
|
)
|
|
$
|
(26.7
|
)
|
|
Loss per share
|
|
|
|
|
|
||
|
Basic
|
$
|
(0.59
|
)
|
|
$
|
(0.14
|
)
|
|
Diluted
|
$
|
(0.59
|
)
|
|
$
|
(0.14
|
)
|
|
Weighted average shares outstanding
|
|
|
|
|
|||
|
Basic
|
229.5
|
|
|
191.9
|
|
||
|
Diluted
|
229.5
|
|
|
191.9
|
|
||
|
|
Three Months Ended March 31,
|
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
(as restated)
|
||||
|
Net loss
|
$
|
(134.4
|
)
|
|
$
|
(26.3
|
)
|
|
|
|
|
|
||||
|
Other comprehensive income (loss), before tax
|
|
|
|
|
|
||
|
Foreign currency translation adjustments:
|
321.5
|
|
|
(352.5
|
)
|
||
|
|
|
|
|
||||
|
Pension and post-retirement plans:
|
|
|
|
||||
|
Tax expense
|
—
|
|
|
(0.5
|
)
|
||
|
Pension and post-retirement plan, net of tax
|
—
|
|
|
(0.5
|
)
|
||
|
|
|
|
|
||||
|
Unrealized loss on available for sale securities:
|
|
|
|
||||
|
Unrealized holding loss on available for sale securities
|
(0.4
|
)
|
|
(0.1
|
)
|
||
|
Unrealized loss on available for sale securities
|
(0.4
|
)
|
|
(0.1
|
)
|
||
|
Tax expense
|
—
|
|
|
—
|
|
||
|
Unrealized loss on available for sale securities, net of tax
|
(0.4
|
)
|
|
(0.1
|
)
|
||
|
|
|
|
|
||||
|
Derivative financial instruments revaluation:
|
|
|
|
||||
|
Unrealized hedging loss arising during the period
|
(11.0
|
)
|
|
—
|
|
||
|
Derivative financial instruments revaluation
|
(11.0
|
)
|
|
—
|
|
||
|
Tax benefit
|
—
|
|
|
—
|
|
||
|
Derivative financial instruments revaluation, net of tax
|
(11.0
|
)
|
|
—
|
|
||
|
Total other comprehensive income (loss), net of tax
|
310.1
|
|
|
(353.1
|
)
|
||
|
Other comprehensive (income) loss attributable to the non-controlling interests
|
(11.7
|
)
|
|
8.7
|
|
||
|
Other comprehensive income (loss) attributable to common shareholders
|
298.4
|
|
|
(344.4
|
)
|
||
|
|
|
|
|
||||
|
Comprehensive income (loss)
|
164.0
|
|
|
(370.7
|
)
|
||
|
Comprehensive income attributable to the non-controlling interests
|
(0.4
|
)
|
|
(0.4
|
)
|
||
|
Comprehensive income (loss) attributable to common stockholders
|
$
|
163.6
|
|
|
$
|
(371.1
|
)
|
|
|
March 31,
|
|
December 31,
|
||||
|
|
2016
|
|
2015
|
||||
|
Assets
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
329.7
|
|
|
$
|
432.2
|
|
|
Restricted cash
|
0.8
|
|
|
0.3
|
|
||
|
Accounts receivable, net of allowance for doubtful accounts of $18.5
and $14.4 at March 31, 2016 and December 31, 2015, respectively |
1,172.8
|
|
|
1,023.0
|
|
||
|
Inventories
|
612.5
|
|
|
517.5
|
|
||
|
Note receivable
|
—
|
|
|
125.0
|
|
||
|
Prepaid expenses and other current assets
|
180.3
|
|
|
172.5
|
|
||
|
Total current assets
|
2,296.1
|
|
|
2,270.5
|
|
||
|
Property, plant and equipment, net
|
496.5
|
|
|
491.6
|
|
||
|
Goodwill
|
4,247.9
|
|
|
4,021.9
|
|
||
|
Intangible assets, net
|
3,453.6
|
|
|
3,314.3
|
|
||
|
Other assets
|
98.6
|
|
|
91.9
|
|
||
|
Total assets
|
$
|
10,592.7
|
|
|
$
|
10,190.2
|
|
|
Liabilities & Stockholders' Equity
|
|
|
|
|
|
||
|
Accounts payable
|
419.8
|
|
|
450.3
|
|
||
|
Current installments of long-term debt and revolving credit facilities
|
188.9
|
|
|
54.7
|
|
||
|
Accrued salaries, wages and employee benefits
|
60.8
|
|
|
78.1
|
|
||
|
Accrued income taxes payable
|
69.8
|
|
|
65.1
|
|
||
|
Accrued expenses and other current liabilities
|
436.3
|
|
|
414.2
|
|
||
|
Total current liabilities
|
1,175.6
|
|
|
1,062.4
|
|
||
|
Long-term debt and capital lease obligations
|
5,218.4
|
|
|
5,173.6
|
|
||
|
Long-term retirement benefits, less current portion
|
81.8
|
|
|
80.5
|
|
||
|
Long-term deferred income taxes
|
723.8
|
|
|
678.8
|
|
||
|
Long-term contingent consideration
|
73.5
|
|
|
70.7
|
|
||
|
Other long-term liabilities
|
223.6
|
|
|
205.0
|
|
||
|
Total liabilities
|
7,496.7
|
|
|
7,271.0
|
|
||
|
Commitments and contingencies (Note 15)
|
|
|
|
|
|
||
|
Redeemable preferred stock - Series B
|
645.9
|
|
|
645.9
|
|
||
|
Stockholders' Equity
|
|
|
|
|
|
||
|
Preferred stock - Series A
|
—
|
|
|
—
|
|
||
|
Common stock 400,000,000 shares authorized, 229,523,697 and 229,464,157 shares issued and outstanding at March 31, 2016 and December 31, 2015, respectively
|
2.3
|
|
|
2.3
|
|
||
|
Additional paid-in capital
|
3,521.7
|
|
|
3,520.4
|
|
||
|
Accumulated deficit
|
(667.5
|
)
|
|
(532.7
|
)
|
||
|
Accumulated other comprehensive loss
|
(587.7
|
)
|
|
(886.1
|
)
|
||
|
Total stockholders' equity
|
2,268.8
|
|
|
2,103.9
|
|
||
|
Non-controlling interests
|
181.3
|
|
|
169.4
|
|
||
|
Total equity
|
2,450.1
|
|
|
2,273.3
|
|
||
|
Total liabilities, redeemable preferred shares and equity
|
$
|
10,592.7
|
|
|
$
|
10,190.2
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2016
|
|
2015
|
||||
|
|
|
|
(as restated)
|
||||
|
Cash flows from operating activities:
|
|
|
|
||||
|
Net cash flows (used in) provided by operating activities
|
$
|
(210.4
|
)
|
|
$
|
2.8
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
||
|
Change in restricted cash
|
(0.5
|
)
|
|
600.0
|
|
||
|
Capital expenditures
|
(11.6
|
)
|
|
(20.8
|
)
|
||
|
Investment in registrations of products
|
(7.5
|
)
|
|
(8.4
|
)
|
||
|
Proceeds from disposal of property, plant and equipment
|
2.2
|
|
|
—
|
|
||
|
Settlement of derivatives
|
(1.1
|
)
|
|
—
|
|
||
|
Acquisition of businesses, net of acquired cash
|
(1.2
|
)
|
|
(2,862.1
|
)
|
||
|
Other, net
|
(0.2
|
)
|
|
0.2
|
|
||
|
Net cash flows used in investing activities
|
(19.9
|
)
|
|
(2,291.1
|
)
|
||
|
Cash flows from financing activities:
|
|
|
|
|
|
||
|
Proceeds from issuance of debt, net of discount and premium
|
1.2
|
|
|
2,084.0
|
|
||
|
Change in revolving credit facilities, net
|
132.5
|
|
|
157.9
|
|
||
|
Repayments of borrowings
|
(8.7
|
)
|
|
(3.6
|
)
|
||
|
Proceeds from issuance of common stock, net
|
0.2
|
|
|
1.0
|
|
||
|
Payment of debt financing fees
|
(0.1
|
)
|
|
(44.6
|
)
|
||
|
Change in factored liabilities
|
(3.5
|
)
|
|
4.2
|
|
||
|
Other, net
|
(0.9
|
)
|
|
—
|
|
||
|
Net cash flows provided by financing activities
|
120.7
|
|
|
2,198.9
|
|
||
|
Effect of exchange rate changes on cash and cash equivalents
|
7.1
|
|
|
(10.6
|
)
|
||
|
Net decrease in cash and cash equivalents
|
(102.5
|
)
|
|
(100.0
|
)
|
||
|
Cash and cash equivalents at beginning of period
|
432.2
|
|
|
397.3
|
|
||
|
Cash and cash equivalents at end of period
|
$
|
329.7
|
|
|
$
|
297.3
|
|
|
Non-cash Investing Activities
|
|
|
|
|
|
||
|
Settlement of Note Receivable in exchange for OMG Malaysia
|
$
|
125.0
|
|
|
$
|
—
|
|
|
Acquisition of OMG Malaysia through the settlement of Note Receivable
|
$
|
(125.0
|
)
|
|
$
|
—
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Additional
Paid-in Capital |
|
Accumulated
Deficit |
|
Accumulated Other Comprehensive (Loss) Income
|
|
Total
Stockholders' Equity |
|
Non-
controlling Interest |
|
Total Equity
|
||||||||||||||||||
|
Balance at December 31, 2015
|
2,000,000
|
|
|
$
|
—
|
|
|
229,464,157
|
|
|
$
|
2.3
|
|
|
$
|
3,520.4
|
|
|
$
|
(532.7
|
)
|
|
$
|
(886.1
|
)
|
|
$
|
2,103.9
|
|
|
$
|
169.4
|
|
|
$
|
2,273.3
|
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(134.8
|
)
|
|
—
|
|
|
(134.8
|
)
|
|
0.4
|
|
|
(134.4
|
)
|
||||||||
|
Other comprehensive loss, net of taxes
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
298.4
|
|
|
298.4
|
|
|
11.7
|
|
|
310.1
|
|
||||||||
|
Issuance of common stock to former non-founder director for exercise of stock options
|
—
|
|
|
—
|
|
|
7,642
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
16,499
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
0.2
|
|
|
(0.2
|
)
|
|
—
|
|
||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
35,399
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
|
0.2
|
|
||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
||||||||
|
Balance at March 31, 2016
|
2,000,000
|
|
|
$
|
—
|
|
|
229,523,697
|
|
|
$
|
2.3
|
|
|
$
|
3,521.7
|
|
|
$
|
(667.5
|
)
|
|
$
|
(587.7
|
)
|
|
$
|
2,268.8
|
|
|
$
|
181.3
|
|
|
$
|
2,450.1
|
|
|
|
Preferred Stock
|
|
Common Stock
|
|
|
|
|
|
Accumulated
Other
Comprehensive
Loss
|
|
|
|
|
|
|
||||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Additional
Paid-in
Capital
|
|
Accumulated
Deficit
|
|
|
Total
Stockholders'
Equity
|
|
Non-
controlling
Interest
|
|
Total Equity
|
|||||||||||||||||||
|
Balance at December 31, 2014
|
2,000,000
|
|
|
$
|
—
|
|
|
182,066,980
|
|
|
$
|
1.9
|
|
|
$
|
2,812.4
|
|
|
$
|
(224.1
|
)
|
|
$
|
(130.6
|
)
|
|
$
|
2,459.6
|
|
|
$
|
93.0
|
|
|
$
|
2,552.6
|
|
|
Net loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(26.7
|
)
|
|
—
|
|
|
(26.7
|
)
|
|
0.4
|
|
|
(26.3
|
)
|
||||||||
|
Other comprehensive loss, net of taxes (as restated)
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(344.4
|
)
|
|
(344.4
|
)
|
|
(8.7
|
)
|
|
(353.1
|
)
|
||||||||
|
Issuance of common stock to Founder Entities as stock dividend on Series A Preferred Stock declared on 12/31/14
|
—
|
|
|
—
|
|
|
10,050,290
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||||
|
Issuance of common stock to former non-founder director for exercise of stock options
|
—
|
|
|
—
|
|
|
75,000
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
—
|
|
|
0.9
|
|
|
—
|
|
|
0.9
|
|
||||||||
|
Conversion of PDH Common Stock into common stock
|
—
|
|
|
—
|
|
|
21,316
|
|
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
|
0.2
|
|
|
(0.2
|
)
|
|
—
|
|
||||||||
|
Issuance of common stock under ESPP
|
—
|
|
|
—
|
|
|
7,986
|
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
—
|
|
|
0.1
|
|
|
—
|
|
|
0.1
|
|
||||||||
|
Equity compensation expense
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
—
|
|
|
0.7
|
|
|
—
|
|
|
0.7
|
|
||||||||
|
Acquisition of non-controlling interest with Arysta Acquisition
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
24.6
|
|
|
24.6
|
|
||||||||
|
Balance at March 31, 2015 (as restated)
|
2,000,000
|
|
|
$
|
—
|
|
|
192,221,572
|
|
|
$
|
1.9
|
|
|
$
|
2,814.3
|
|
|
$
|
(250.8
|
)
|
|
$
|
(475.0
|
)
|
|
$
|
2,090.4
|
|
|
$
|
109.1
|
|
|
$
|
2,199.5
|
|
|
(amounts in millions)
|
Three Months Ended March 31, 2016
|
|
Three Months Ended March 31, 2015
|
||||
|
OMG Malaysia
|
$
|
5.5
|
|
|
$
|
—
|
|
|
Alent
|
219.6
|
|
|
—
|
|
||
|
OMG
|
27.2
|
|
|
—
|
|
||
|
Arysta
|
283.6
|
|
|
177.5
|
|
||
|
Total
|
$
|
535.9
|
|
|
$
|
177.5
|
|
|
(amounts in millions)
|
Three Months Ended March 31, 2016
|
|
Three Months Ended March 31, 2015
|
||||
|
OMG Malaysia
|
$
|
(0.6
|
)
|
|
$
|
—
|
|
|
Alent
|
(1.4
|
)
|
|
—
|
|
||
|
OMG
|
(1.0
|
)
|
|
—
|
|
||
|
Arysta
|
(70.8
|
)
|
|
(4.3
|
)
|
||
|
Total
|
$
|
(73.8
|
)
|
|
$
|
(4.3
|
)
|
|
(amounts in millions)
|
OMG Malaysia
|
|
Alent
|
|
OMG Businesses
|
||||||
|
Consideration
|
|
|
|
|
|
||||||
|
Cash, net
|
$
|
(1.3
|
)
|
|
$
|
1,507.0
|
|
|
$
|
239.1
|
|
|
Equity Instruments
|
—
|
|
|
231.4
|
|
|
—
|
|
|||
|
Note receivable settlement
|
125.0
|
|
|
—
|
|
|
—
|
|
|||
|
Total Consideration
|
$
|
123.7
|
|
|
$
|
1,738.4
|
|
|
$
|
239.1
|
|
|
|
|
|
|
|
|
||||||
|
Acquisition costs
|
$
|
0.1
|
|
|
$
|
29.3
|
|
|
$
|
7.4
|
|
|
|
|
|
|
|
|
||||||
|
Identifiable Assets acquired and Liabilities Assumed
|
|
|
|
|
|
||||||
|
Accounts receivable
|
$
|
4.3
|
|
|
$
|
177.4
|
|
|
$
|
33.1
|
|
|
- less uncollectible
|
—
|
|
|
(1.8
|
)
|
|
(1.6
|
)
|
|||
|
Accounts receivable - fair value
|
4.3
|
|
|
175.6
|
|
|
31.5
|
|
|||
|
Inventories
|
7.2
|
|
|
116.1
|
|
|
13.2
|
|
|||
|
Other current assets
|
0.2
|
|
|
29.3
|
|
|
1.6
|
|
|||
|
Property, plant and equipment
|
4.7
|
|
|
192.2
|
|
|
35.1
|
|
|||
|
Identifiable intangible assets
|
59.0
|
|
|
682.9
|
|
|
77.9
|
|
|||
|
Other assets
|
—
|
|
|
37.6
|
|
|
0.2
|
|
|||
|
Current Liabilities
|
(3.5
|
)
|
|
(181.8
|
)
|
|
(21.5
|
)
|
|||
|
Non-current deferred tax liability
|
(15.1
|
)
|
|
(138.6
|
)
|
|
(13.6
|
)
|
|||
|
Other long term liabilities
|
—
|
|
|
(316.9
|
)
|
|
(4.0
|
)
|
|||
|
Total identifiable net assets
|
56.8
|
|
|
596.4
|
|
|
120.4
|
|
|||
|
Goodwill
|
66.9
|
|
|
1,142.0
|
|
|
118.7
|
|
|||
|
Total purchase price
|
$
|
123.7
|
|
|
$
|
1,738.4
|
|
|
$
|
239.1
|
|
|
|
OMG Malaysia
|
|
Alent
|
|
OMG Businesses
|
|
Total
|
||||||||||||||||||||
|
(amounts in millions)
|
Fair Value
|
|
Weighted average useful life (years)
|
|
Fair Value
|
|
Weighted average useful life (years)
|
|
Fair Value
|
|
Weighted average useful life (years)
|
|
Fair Value
|
|
Weighted average useful life (years)
|
||||||||||||
|
Customer lists
|
$
|
45.0
|
|
|
25.0
|
|
|
$
|
391.4
|
|
|
15.5
|
|
|
$
|
49.0
|
|
|
24.5
|
|
|
$
|
485.4
|
|
|
18.0
|
|
|
Developed technology
|
14.0
|
|
|
10.0
|
|
|
203.3
|
|
|
10.0
|
|
|
28.0
|
|
|
10.0
|
|
|
245.3
|
|
|
10.0
|
|
||||
|
Tradenames
|
—
|
|
|
—
|
|
|
85.8
|
|
(1)
|
20.0
|
|
|
0.9
|
|
|
10.0
|
|
|
86.7
|
|
|
19.1
|
|
||||
|
In process - R&D
|
—
|
|
|
—
|
|
|
2.4
|
|
(2)
|
—
|
|
|
—
|
|
|
—
|
|
|
2.4
|
|
|
—
|
|
||||
|
Total
|
$
|
59.0
|
|
|
23.3
|
|
|
$
|
682.9
|
|
|
14.2
|
|
|
$
|
77.9
|
|
|
21.7
|
|
|
$
|
819.8
|
|
|
16.3
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Revenue
|
$
|
826.7
|
|
|
$
|
897.2
|
|
|
Net loss attributable to stockholders
|
$
|
(119.2
|
)
|
|
$
|
(64.4
|
)
|
|
(amounts in millions)
|
March 31,
2016 |
|
December 31, 2015
|
||||
|
Finished goods
|
$
|
399.4
|
|
|
$
|
340.1
|
|
|
Work in process
|
33.9
|
|
|
28.5
|
|
||
|
Raw materials and supplies
|
179.2
|
|
|
148.9
|
|
||
|
Total inventory, net
|
$
|
612.5
|
|
|
$
|
517.5
|
|
|
(amounts in millions)
|
|
March 31,
2016 |
|
December 31, 2015
|
||||
|
Land and leasehold improvements
|
|
$
|
111.5
|
|
|
$
|
107.9
|
|
|
Buildings and improvements
|
|
149.3
|
|
|
143.8
|
|
||
|
Machinery, equipment, fixtures and software
|
|
283.3
|
|
|
276.8
|
|
||
|
Assets under capital lease
|
|
|
|
|
||||
|
Land and buildings
|
|
8.3
|
|
|
6.4
|
|
||
|
Machinery and equipment
|
|
5.4
|
|
|
5.1
|
|
||
|
Total Property, plant and equipment
|
|
557.8
|
|
|
540.0
|
|
||
|
Accumulated depreciation
|
|
(78.3
|
)
|
|
(64.3
|
)
|
||
|
Accumulated amortization of capital leases
|
|
(6.4
|
)
|
|
(5.5
|
)
|
||
|
Total accumulated depreciation and amortization
|
|
473.1
|
|
|
470.2
|
|
||
|
Construction in process
|
|
23.4
|
|
|
21.4
|
|
||
|
Property, plant and equipment, net
|
|
$
|
496.5
|
|
|
$
|
491.6
|
|
|
(amounts in millions)
|
Performance
Solutions
|
|
Agricultural Solutions
|
|
Total
|
||||||
|
December 31, 2015
|
$
|
2,147.2
|
|
|
$
|
1,874.7
|
|
|
$
|
4,021.9
|
|
|
Addition from acquisitions
|
66.9
|
|
|
—
|
|
|
66.9
|
|
|||
|
Purchase accounting adjustments
|
3.6
|
|
|
0.2
|
|
|
3.8
|
|
|||
|
Foreign currency translation
|
34.2
|
|
|
121.1
|
|
|
155.3
|
|
|||
|
March 31, 2016
|
$
|
2,251.9
|
|
|
$
|
1,996.0
|
|
|
$
|
4,247.9
|
|
|
|
|
|
March 31, 2016
|
|
December 31, 2015
|
||||||||||||||||||||
|
(amounts in millions)
|
Weighted average useful life (years)
|
|
Gross Carrying
Amount and Foreign Exchange
|
|
Accumulated
Amortization and
Foreign Exchange
|
|
Net Book
Value
|
|
Gross Carrying
Amount and Foreign Exchange
|
|
Accumulated
Amortization and
Foreign Exchange
|
|
Net Book
Value
|
||||||||||||
|
Customer lists
|
20.5
|
|
$
|
1,250.5
|
|
|
$
|
(80.3
|
)
|
|
$
|
1,170.2
|
|
|
$
|
1,297.2
|
|
|
$
|
(184.0
|
)
|
|
$
|
1,113.2
|
|
|
Developed technology
|
11.8
|
|
2,006.0
|
|
|
(119.0
|
)
|
|
1,887.0
|
|
|
2,260.9
|
|
|
(440.4
|
)
|
|
1,820.5
|
|
||||||
|
Tradenames
|
12.4
|
|
22.2
|
|
|
(3.7
|
)
|
|
18.5
|
|
|
24.2
|
|
|
(5.4
|
)
|
|
18.8
|
|
||||||
|
Non-compete agreements
|
5.0
|
|
1.9
|
|
|
(0.6
|
)
|
|
1.3
|
|
|
1.9
|
|
|
(0.5
|
)
|
|
1.4
|
|
||||||
|
Total
|
15.1
|
|
$
|
3,280.6
|
|
|
$
|
(203.6
|
)
|
|
$
|
3,077.0
|
|
|
$
|
3,584.2
|
|
|
$
|
(630.3
|
)
|
|
$
|
2,953.9
|
|
|
|
Three Months Ended March 31, 2016
|
||||||||||
|
|
Total
|
|
RSUs
|
|
Stock Options
|
||||||
|
|
|
Equity
Classified
|
|
Liability Classified
|
|
||||||
|
Outstanding at December 31, 2015
|
1,006,436
|
|
|
501,634
|
|
|
329,802
|
|
|
175,000
|
|
|
Granted
|
1,890,998
|
|
|
1,526,415
|
|
|
—
|
|
|
364,583
|
|
|
Exercised/Issued
|
(7,642
|
)
|
|
(7,642
|
)
|
|
—
|
|
|
—
|
|
|
Forfeited
|
(51,337
|
)
|
|
(51,337
|
)
|
|
—
|
|
|
—
|
|
|
Outstanding at March 31, 2016
|
2,838,455
|
|
|
1,969,070
|
|
|
329,802
|
|
|
539,583
|
|
|
|
Black-Scholes Input Assumptions
|
||
|
Weighted average expected term (years)
|
6.0
|
|
|
|
Expected Volatility
|
53.0
|
%
|
|
|
Risk-free rate
|
1.56
|
%
|
|
|
Expected dividend rate
|
—
|
%
|
|
|
Fair value price
|
$
|
4.32
|
|
|
|
Three Months Ended March 31,
|
||||||||||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||||||||||
|
Pension & SERP Benefits:
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||
|
Net periodic (benefit) cost:
|
|
|
|
|
|
|
|
||||||||
|
Service cost
|
$
|
—
|
|
|
$
|
0.4
|
|
|
$
|
—
|
|
|
$
|
0.2
|
|
|
Interest cost on the projected benefit obligation
|
2.5
|
|
|
0.8
|
|
|
1.6
|
|
|
0.5
|
|
||||
|
Expected return on plan assets
|
(2.9
|
)
|
|
(0.7
|
)
|
|
(2.4
|
)
|
|
(0.5
|
)
|
||||
|
Amortization of prior service cost
|
—
|
|
|
0.2
|
|
|
—
|
|
|
—
|
|
||||
|
Net periodic (benefit) cost
|
$
|
(0.4
|
)
|
|
$
|
0.7
|
|
|
$
|
(0.8
|
)
|
|
$
|
0.2
|
|
|
|
Three Months Ended March 31,
|
||||||||||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||||||||||
|
Post-retirement Benefits:
|
Domestic
|
|
Foreign
|
|
Domestic
|
|
Foreign
|
||||||||
|
Net periodic cost:
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Interest cost on the projected benefit obligation
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
Net periodic cost
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
(amounts in millions)
|
March 31,
2016 |
|
December 31, 2015
|
||||
|
Borrowings under lines of credit,
weighted average interest rate of 3.43% and 4.28% at March 31, 2016 and December 31, 2015, respectively |
$
|
149.2
|
|
|
$
|
16.7
|
|
|
|
|
|
|
||||
|
USD Notes, due 2022,
interest at 6.50%, net of unamortized premium and debt issuance costs of $18.1million and $18.9 million at March 31, 2016 and December 31, 2015, respectively |
1,081.9
|
|
|
1,081.1
|
|
||
|
EUR Notes, due 2023,
interest at 6.00%, net of debt issuance costs of $5.9 million and $6.1 million at March 31, 2016 and December 31, 2015, respectively |
392.2
|
|
|
374.0
|
|
||
|
USD Notes, due 2021,
interest at 10.375%, net of debt issuance costs of $12.0 million and $12.5 million at March 31, 2016 and December 31, 2015, respectively |
488.0
|
|
|
487.5
|
|
||
|
First lien secured credit facility, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of debt issuance costs of $0.5 million and $0.6 million at March 31, 2016 and December 31, 2015, respectively |
733.7
|
|
|
735.6
|
|
||
|
USD Incremental Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and debt issuance costs of $5.1 million and $5.4 million at March 31, 2016 and December 31, 2015, respectively |
290.4
|
|
|
290.8
|
|
||
|
CAS U.S. Dollar Tranche B Term Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and debt issuance costs of $6.1 million and $6.4 million at March 31, 2016 and December 31, 2015, respectively |
122.0
|
|
|
121.9
|
|
||
|
Arysta U.S. Dollar Tranche B-2 Term Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and debt issuance costs of $13.1 million and $13.9 million at March 31, 2016 and December 31, 2015, respectively |
480.7
|
|
|
481.2
|
|
||
|
Alent U.S. Dollar Tranche B-3 Term Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and debt issuance costs of $38.3 million and $40.5 million at March 31, 2016 and December 31, 2015, respectively |
1,001.5
|
|
|
1,001.8
|
|
||
|
CAS EURO Tranche C-1 Term Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount of $0.9 million and $0.9 million at March 31, 2016 and December 31, 2015, respectively |
228.8
|
|
|
219.0
|
|
||
|
Arysta EURO Tranche C-1 Term Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and debt issuance costs of $2.0 million and $2.1 million at March 31, 2016 and December 31, 2015, respectively |
91.2
|
|
|
87.2
|
|
||
|
Alent EURO Tranche C-2 Term Loan, due 2020,
interest at the greater of 5.50% or LIBOR plus 4.50%, net of unamortized discount and debt issuance costs of $11.9 million and $11.9 million at March 31, 2016 and December 31, 2015, respectively |
327.7
|
|
|
313.0
|
|
||
|
Other
|
20.0
|
|
|
18.5
|
|
||
|
Total debt and capital lease obligations
|
5,258.1
|
|
|
5,211.6
|
|
||
|
Less: current portion debt and capital lease obligations
|
(39.7
|
)
|
|
(38.0
|
)
|
||
|
Total long-term debt and capital lease obligations
|
$
|
5,218.4
|
|
|
$
|
5,173.6
|
|
|
(amounts in millions)
|
Principal Payments
|
||
|
Year ending December 31,
|
|||
|
2016 - remaining
|
$
|
41.1
|
|
|
2017
|
34.9
|
|
|
|
2018
|
34.7
|
|
|
|
2019
|
34.6
|
|
|
|
2020
|
3,226.6
|
|
|
|
2021
|
500.5
|
|
|
|
Thereafter
|
1,499.6
|
|
|
|
Total
|
$
|
5,372.0
|
|
|
(amounts in millions)
|
|
|
|
March 31,
2016 |
|
December 31, 2015
|
||||
|
|
|
|
|
U.S. Dollar Amount
|
|
U.S. Dollar Amount
|
||||
|
Derivatives designated as hedging instruments
|
|
Liabilities Balance Sheet location
|
|
|
|
|
||||
|
Interest rate swaps
|
|
Other long-term liabilities
|
|
$
|
(23.5
|
)
|
|
$
|
(12.5
|
)
|
|
Derivatives not designated as hedging instruments:
|
|
Assets Balance Sheet location
|
|
|
|
|
|
|
||
|
Foreign exchange and metals contracts
|
|
Prepaid expenses and other current assets
|
|
4.3
|
|
|
1.1
|
|
||
|
Foreign exchange contracts
|
|
Other Assets
|
|
—
|
|
|
1.0
|
|
||
|
|
|
Liabilities Balance Sheet location
|
|
|
|
|
|
|
||
|
Foreign exchange and metals contracts
|
|
Accrued expenses and other current liabilities
|
|
(9.5
|
)
|
|
(1.0
|
)
|
||
|
Net derivative contract liability
|
|
|
|
$
|
(28.7
|
)
|
|
$
|
(11.4
|
)
|
|
Financial assets
|
Amounts offset
|
|
Amounts not offset
|
|
Net
|
||||||||||||||||
|
March 31, 2016
|
Gross assets
|
|
Gross liabilities offset
|
|
Net amounts presented
|
|
Financial instruments
|
|
Cash collateral received
|
|
|
||||||||||
|
Derivative assets
|
$
|
3.3
|
|
|
—
|
|
|
$
|
3.3
|
|
|
(0.3
|
)
|
|
$
|
—
|
|
|
$
|
3.0
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||
|
Financial liabilities
|
Amounts offset
|
|
Amounts not offset
|
|
Net
|
||||||||||||||||
|
March 31, 2016
|
Gross liabilities
|
|
Gross assets offset
|
|
Net amounts presented
|
|
Financial instruments
|
|
Cash collateral pledged
|
|
|
||||||||||
|
Derivative liabilities
|
$
|
7.7
|
|
|
—
|
|
|
$
|
7.7
|
|
|
(2.2
|
)
|
|
$
|
(1.9
|
)
|
|
$
|
3.6
|
|
|
•
|
Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.
|
|
•
|
Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model-derived valuations whose inputs are observable or whose significant valuation drivers are observable.
|
|
•
|
Level 3 – significant inputs to the valuation model are unobservable and/or reflect the Company’s market assumptions.
|
|
|
|
|
Fair Value Measurement Using
|
||||||||||||
|
(amounts in millions)
|
March 31,
2016 |
|
Quoted prices in
active markets
(Level 1)
|
|
Significant
other observable
inputs
(Level 2)
|
|
Significant
unobservable
inputs
(Level 3)
|
||||||||
|
Asset Category
|
|
|
|
|
|
|
|
||||||||
|
Cash equivalents
|
$
|
9.2
|
|
|
$
|
1.0
|
|
|
$
|
8.2
|
|
|
$
|
—
|
|
|
Available for sale equity securities
|
6.8
|
|
|
6.2
|
|
|
0.6
|
|
|
—
|
|
||||
|
Derivatives
|
4.3
|
|
|
—
|
|
|
4.3
|
|
|
—
|
|
||||
|
Total
|
$
|
20.3
|
|
|
$
|
7.2
|
|
|
$
|
13.1
|
|
|
$
|
—
|
|
|
Liability Category
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Long-term contingent consideration
|
$
|
73.5
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
73.5
|
|
|
Derivatives
|
33.0
|
|
|
—
|
|
|
33.0
|
|
|
—
|
|
||||
|
Total
|
$
|
106.5
|
|
|
$
|
—
|
|
|
$
|
33.0
|
|
|
$
|
73.5
|
|
|
|
|
|
Fair Value Measurement Using
|
||||||||||||
|
(amounts in millions)
|
December 31, 2015
|
|
Quoted prices in
active markets
(Level 1)
|
|
Significant
other observable
inputs
(Level 2)
|
|
Significant
unobservable
inputs
(Level 3)
|
||||||||
|
Asset Category
|
|
|
|
|
|
|
|
||||||||
|
Cash equivalents
|
$
|
59.4
|
|
|
$
|
2.9
|
|
|
$
|
56.5
|
|
|
$
|
—
|
|
|
Available for sale equity securities
|
6.6
|
|
|
5.8
|
|
|
0.8
|
|
|
—
|
|
||||
|
Derivatives
|
2.1
|
|
|
—
|
|
|
2.1
|
|
|
—
|
|
||||
|
Total
|
$
|
68.1
|
|
|
$
|
8.7
|
|
|
$
|
59.4
|
|
|
$
|
—
|
|
|
Liability Category
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Long-term contingent consideration
|
$
|
70.7
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
70.7
|
|
|
Derivatives
|
13.5
|
|
|
—
|
|
|
13.5
|
|
|
—
|
|
||||
|
Total
|
$
|
84.2
|
|
|
$
|
—
|
|
|
$
|
13.5
|
|
|
$
|
70.7
|
|
|
(amounts in millions)
|
Long-term contingent consideration
|
||
|
Fair value measurements using significant unobservable inputs (Level 3)
|
March 31, 2016
|
||
|
Beginning balance
|
$
|
70.7
|
|
|
Changes in fair value
|
2.8
|
|
|
|
Purchases, sales and settlements
(1)
|
—
|
|
|
|
Transfers into Level 3
|
—
|
|
|
|
Transfers out of Level 3
|
—
|
|
|
|
Ending balance
|
$
|
73.5
|
|
|
(amounts in millions)
|
March 31, 2016
|
|
December 31, 2015
|
||||||||||||
|
|
Carrying
Value
|
|
Fair Value
|
|
Carrying
Value
|
|
Fair Value
|
||||||||
|
USD Notes, due 2022
|
$
|
1,081.9
|
|
|
$
|
932.3
|
|
|
$
|
1,081.1
|
|
|
$
|
946.3
|
|
|
EUR Notes, due 2023
|
392.2
|
|
|
333.1
|
|
|
374.0
|
|
|
326.7
|
|
||||
|
USD Notes, due 2021
|
488.0
|
|
|
485.0
|
|
|
487.5
|
|
|
500.0
|
|
||||
|
First Lien Credit Facility
|
733.7
|
|
|
711.8
|
|
|
735.6
|
|
|
710.3
|
|
||||
|
USD Incremental Loan
|
290.4
|
|
|
286.4
|
|
|
290.8
|
|
|
285.8
|
|
||||
|
CAS U.S. Dollar Tranche B Term Loan
|
122.0
|
|
|
124.1
|
|
|
121.9
|
|
|
123.9
|
|
||||
|
Arysta U.S. Dollar Tranche B-2 Term Loan
|
480.7
|
|
|
478.9
|
|
|
481.2
|
|
|
477.7
|
|
||||
|
Alent U.S. Dollar Tranche B-3 Term Loan
|
1,001.5
|
|
|
1,008.6
|
|
|
1,001.8
|
|
|
1,005.9
|
|
||||
|
CAS EURO Tranche C-1 Term Loan
|
228.8
|
|
|
223.9
|
|
|
219.0
|
|
|
215.4
|
|
||||
|
Arysta EURO Tranche C-1 Term Loan
|
91.2
|
|
|
90.8
|
|
|
87.2
|
|
|
87.5
|
|
||||
|
Alent EURO Tranche C-2 Term Loan
|
327.7
|
|
|
341.5
|
|
|
313.0
|
|
|
321.4
|
|
||||
|
Enthone financing liability
|
14.5
|
|
|
14.5
|
|
|
13.0
|
|
|
13.0
|
|
||||
|
Capital lease obligations
|
5.5
|
|
|
5.3
|
|
|
5.5
|
|
|
5.3
|
|
||||
|
Total
|
$
|
5,258.1
|
|
|
$
|
5,036.2
|
|
|
$
|
5,211.6
|
|
|
$
|
5,019.2
|
|
|
|
Three Months Ended March 31, 2016
|
||||||||||||||||||||||
|
(amounts in millions)
|
Foreign Currency Translation Adjustments
|
|
Pension and Post-retirement Plans
|
|
Unrealized Gain on Available for Sale Securities
|
|
Derivative Financial Instrument Revaluation
|
|
Non-Controlling Interests
|
|
Accumulated Other Comprehensive Loss
|
||||||||||||
|
Balance at December 31, 2015
|
$
|
(899.3
|
)
|
|
$
|
(26.3
|
)
|
|
$
|
1.2
|
|
|
$
|
(8.1
|
)
|
|
$
|
46.4
|
|
|
$
|
(886.1
|
)
|
|
Other comprehensive (loss) income before reclassifications, net
|
321.5
|
|
|
—
|
|
|
(0.4
|
)
|
|
(13.9
|
)
|
|
(11.7
|
)
|
|
295.5
|
|
||||||
|
Reclassifications, pretax
|
—
|
|
|
—
|
|
|
—
|
|
|
2.9
|
|
|
—
|
|
|
2.9
|
|
||||||
|
Tax benefit reclassified
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||||
|
Balance at March 31, 2016
|
$
|
(577.8
|
)
|
|
$
|
(26.3
|
)
|
|
$
|
0.8
|
|
|
$
|
(19.1
|
)
|
|
$
|
34.7
|
|
|
$
|
(587.7
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2015
|
||||||||||||||||||||||
|
|
(as restated)
|
||||||||||||||||||||||
|
(amounts in millions)
|
Foreign Currency Translation Adjustments
|
|
Pension and Post-retirement Plans
|
|
Unrealized Gain on Available for Sale Securities
|
|
Derivative Financial Instrument Revaluation
|
|
Non-Controlling Interests
|
|
Accumulated Other Comprehensive Loss
|
||||||||||||
|
Balance at December 31, 2014
|
$
|
(122.2
|
)
|
|
$
|
(14.9
|
)
|
|
$
|
0.1
|
|
|
$
|
—
|
|
|
$
|
6.4
|
|
|
$
|
(130.6
|
)
|
|
Other comprehensive (loss) income before reclassifications, net (as restated)
|
(352.5
|
)
|
|
—
|
|
|
(0.1
|
)
|
|
—
|
|
|
8.7
|
|
|
(343.9
|
)
|
||||||
|
Tax expense reclassified
|
—
|
|
|
(0.5
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(0.5
|
)
|
||||||
|
Balance at March 31, 2015
|
$
|
(474.7
|
)
|
|
$
|
(15.4
|
)
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
15.1
|
|
|
$
|
(475.0
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions, except per share amounts)
|
2016
|
|
2015
|
||||
|
Net loss attributable to common stockholders
|
$
|
(134.8
|
)
|
|
$
|
(26.7
|
)
|
|
|
|
|
|
||||
|
Basic weighted average common stock outstanding
|
229.5
|
|
|
191.9
|
|
||
|
Convertible and performance-based stock
(1)
|
—
|
|
|
—
|
|
||
|
Dilutive weighted average common stock outstanding
|
229.5
|
|
|
191.9
|
|
||
|
Loss per share attributable to common stockholders:
|
|
|
|
|
|
||
|
Basic
|
$
|
(0.59
|
)
|
|
$
|
(0.14
|
)
|
|
Diluted
|
$
|
(0.59
|
)
|
|
$
|
(0.14
|
)
|
|
|
|
|
|
||||
|
Dividends per share paid to common shareholders
|
$
|
—
|
|
|
$
|
—
|
|
|
|
Three Months Ended March 31,
|
||||
|
(amounts in thousands)
|
2016
|
|
2015
|
||
|
Shares contingently issuable to Founder Entities as stock dividend on Series A Preferred Stock
|
—
|
|
|
2,168
|
|
|
Shares issuable upon conversion of PDH Common Stock
|
8,052
|
|
|
8,619
|
|
|
Shares issuable upon conversion of Series A Preferred Stock
|
2,000
|
|
|
2,000
|
|
|
Shares issuable upon conversion of Series B Convertible Preferred Stock
|
22,108
|
|
|
11,299
|
|
|
Shares contingently issuable for the contingent consideration
|
8,704
|
|
|
1,333
|
|
|
Stock options
|
—
|
|
|
87
|
|
|
Restricted stock shares and units
|
—
|
|
|
57
|
|
|
Shares issuable under the ESPP
|
1
|
|
|
—
|
|
|
|
40,865
|
|
|
25,563
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Rent Expense
|
$
|
9.1
|
|
|
$
|
4.3
|
|
|
(amounts in millions)
|
Operating
Lease
Payment
|
||
|
As of March 31, 2016
|
|||
|
2016, remaining
|
$
|
24.7
|
|
|
2017
|
23.3
|
|
|
|
2018
|
15.1
|
|
|
|
2019
|
10.3
|
|
|
|
2020
|
8.6
|
|
|
|
2021
|
7.8
|
|
|
|
Thereafter
|
27.9
|
|
|
|
|
$
|
117.7
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
AROs, beginning of period
|
$
|
17.5
|
|
|
$
|
18.5
|
|
|
Accretion expense
|
0.2
|
|
|
0.3
|
|
||
|
Remeasurements
|
0.1
|
|
|
—
|
|
||
|
Payments
|
(0.2
|
)
|
|
—
|
|
||
|
Foreign currency adjustments
|
0.7
|
|
|
(1.4
|
)
|
||
|
AROs, end of period
|
$
|
18.3
|
|
|
$
|
17.4
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Performance Solutions
|
$
|
4.2
|
|
|
$
|
1.5
|
|
|
Agricultural Solutions
|
0.9
|
|
|
0.1
|
|
||
|
Total restructuring
|
$
|
5.1
|
|
|
$
|
1.6
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Cost of sales
|
$
|
(0.4
|
)
|
|
$
|
—
|
|
|
Selling, technical, general and administrative
|
5.5
|
|
|
1.6
|
|
||
|
Total restructuring
|
$
|
5.1
|
|
|
$
|
1.6
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Net Sales (from external customers):
|
|
|
|
||||
|
Performance Solutions
|
$
|
420.0
|
|
|
$
|
180.3
|
|
|
Agricultural Solutions
|
403.8
|
|
|
354.5
|
|
||
|
Consolidated net sales
|
823.8
|
|
|
534.8
|
|
||
|
Adjusted EBITDA:
|
|
|
|
|
|
||
|
Performance Solutions
|
$
|
83.0
|
|
|
$
|
49.0
|
|
|
Agricultural Solutions
|
85.4
|
|
|
83.1
|
|
||
|
Adjusted EBITDA
|
$
|
168.4
|
|
|
$
|
132.1
|
|
|
|
Three months ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Adjusted EBITDA
|
$
|
168.4
|
|
|
$
|
132.1
|
|
|
Adjustments to reconcile to net loss attributable to common stockholders:
|
|
|
|
||||
|
Interest expense, net
|
(93.8
|
)
|
|
(39.4
|
)
|
||
|
Depreciation expense
|
(18.2
|
)
|
|
(8.4
|
)
|
||
|
Amortization expense
|
(64.4
|
)
|
|
(39.8
|
)
|
||
|
Long-term compensation issued in connection with acquisitions
|
(0.3
|
)
|
|
(1.5
|
)
|
||
|
Restructuring expenses
|
(5.1
|
)
|
|
(1.6
|
)
|
||
|
Manufacturer's profit in inventory purchase accounting adjustments
|
(12.0
|
)
|
|
(36.1
|
)
|
||
|
Acquisition and integration costs
|
(18.9
|
)
|
|
(31.3
|
)
|
||
|
Non-cash change in fair value of contingent consideration
|
(2.8
|
)
|
|
(2.7
|
)
|
||
|
Acquisition put option expiration
|
—
|
|
|
3.0
|
|
||
|
Foreign exchange (loss) gains on foreign denominated external and internal debt
|
(66.1
|
)
|
|
24.1
|
|
||
|
Other expenses
|
(2.8
|
)
|
|
—
|
|
||
|
Net loss before income taxes and non-controlling interests
|
(116.0
|
)
|
|
(1.6
|
)
|
||
|
Income tax expense
|
(18.4
|
)
|
|
(24.7
|
)
|
||
|
Net income attributable to the non-controlling interests
|
(0.4
|
)
|
|
(0.4
|
)
|
||
|
Net loss attributable to common stockholders
|
$
|
(134.8
|
)
|
|
$
|
(26.7
|
)
|
|
|
Three Months Ended March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As Restated
|
||||||
|
Other comprehensive income (loss), before tax
|
|
|
|
|
|
||||||
|
Foreign currency translation adjustments:
|
$
|
(425.3
|
)
|
|
$
|
72.8
|
|
|
$
|
(352.5
|
)
|
|
|
|
|
|
|
|
||||||
|
Total other comprehensive income (loss), net of tax
|
$
|
(425.9
|
)
|
|
$
|
72.8
|
|
|
$
|
(353.1
|
)
|
|
Other comprehensive income (loss) attributable to common shareholders
|
(417.2
|
)
|
|
72.8
|
|
|
(344.4
|
)
|
|||
|
|
|
|
|
|
|
||||||
|
Comprehensive income (loss)
|
$
|
(443.5
|
)
|
|
$
|
72.8
|
|
|
$
|
(370.7
|
)
|
|
Comprehensive income (loss) attributable to common stockholders
|
(443.9
|
)
|
|
72.8
|
|
|
(371.1
|
)
|
|||
|
|
March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Assets
|
|
|
|
|
|
||||||
|
Goodwill
|
$
|
2,908.9
|
|
|
$
|
72.8
|
|
|
$
|
2,981.7
|
|
|
Total Assets
|
8,067.9
|
|
|
72.8
|
|
|
8,140.7
|
|
|||
|
|
|
|
|
|
|
||||||
|
Stockholders' Equity
|
|
|
|
|
|
||||||
|
Accumulated other comprehensive loss
|
$
|
(547.8
|
)
|
|
$
|
72.8
|
|
|
$
|
(475.0
|
)
|
|
Total stockholders' equity
|
2,017.6
|
|
|
72.8
|
|
|
2,090.4
|
|
|||
|
Total equity
|
2,126.7
|
|
|
72.8
|
|
|
2,199.5
|
|
|||
|
Total liabilities, redeemable preferred shares and stockholders' equity
|
8,067.9
|
|
|
72.8
|
|
|
8,140.7
|
|
|||
|
|
Three Months Ended March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustments
|
|
As Restated
|
||||||
|
Cash flows from operating activities:
|
|
|
|
|
|
||||||
|
Net cash flows (used in) provided by operating activities
|
$
|
(70.0
|
)
|
|
$
|
72.8
|
|
|
$
|
2.8
|
|
|
Cash flows from investing activities:
|
|
|
|
|
|
||||||
|
Acquisition of businesses, net of acquired cash
|
$
|
(2,789.3
|
)
|
|
$
|
(72.8
|
)
|
|
$
|
(2,862.1
|
)
|
|
Net cash flows used in investing activities
|
(2,218.3
|
)
|
|
(72.8
|
)
|
|
(2,291.1
|
)
|
|||
|
|
Other Comprehensive loss, net of taxes for the three months ended March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Accumulated Other Comprehensive Loss
|
$
|
(417.2
|
)
|
|
$
|
72.8
|
|
|
$
|
(344.4
|
)
|
|
Total Stockholders' Equity
|
(417.2
|
)
|
|
72.8
|
|
|
(344.4
|
)
|
|||
|
Total Equity
|
(425.9
|
)
|
|
72.8
|
|
|
(353.1
|
)
|
|||
|
|
Balance at March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Accumulated Other Comprehensive Loss
|
$
|
(547.8
|
)
|
|
$
|
72.8
|
|
|
$
|
(475.0
|
)
|
|
Total Stockholders' Equity
|
2,017.6
|
|
|
72.8
|
|
|
2,090.4
|
|
|||
|
Total Equity
|
2,126.7
|
|
|
72.8
|
|
|
2,199.5
|
|
|||
|
(in millions)
|
Arysta Purchase Price Allocation
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Consideration
|
|
|
|
|
|
||||||
|
Cash, net
|
$
|
2,789.1
|
|
|
$
|
72.8
|
|
|
$
|
2,861.9
|
|
|
|
|
|
|
|
|
||||||
|
Goodwill
|
$
|
1,697.1
|
|
|
$
|
72.8
|
|
|
$
|
1,769.9
|
|
|
|
|
|
|
|
|
||||||
|
Total purchase price
|
$
|
3,435.0
|
|
|
$
|
72.8
|
|
|
$
|
3,507.8
|
|
|
|
|
|
|
|
|
||||||
|
Goodwill recorded in connection with the Arysta, CAS and Agriphar Acquisitions
|
$
|
2,151.5
|
|
|
$
|
72.8
|
|
|
$
|
2,224.3
|
|
|
|
Changes in carrying amount of Agricultural Solutions goodwill for the three months ended March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Additions from acquisitions
|
$
|
1,697.1
|
|
|
$
|
72.8
|
|
|
$
|
1,769.9
|
|
|
Balance at March 31, 2015
|
1,986.8
|
|
|
72.8
|
|
|
2,059.6
|
|
|||
|
|
|
|
|
|
|
||||||
|
|
Changes in carrying amount of Total goodwill
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Additions from acquisitions
|
$
|
1,697.1
|
|
|
$
|
72.8
|
|
|
$
|
1,769.9
|
|
|
Balance at March 31, 2015
|
2,908.9
|
|
|
72.8
|
|
|
2,981.7
|
|
|||
|
|
Changes in Other comprehensive income (loss) before reclassifications, net for the three month ended March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Foreign Currency Translation Adjustments
|
$
|
(425.3
|
)
|
|
$
|
72.8
|
|
|
$
|
(352.5
|
)
|
|
Accumulated Other Comprehensive Loss
|
(416.7
|
)
|
|
72.8
|
|
|
(343.9
|
)
|
|||
|
|
|
|
|
|
|
||||||
|
|
Balance at March 31, 2015
|
||||||||||
|
(in millions)
|
As Previously Reported
|
|
Adjustment
|
|
As restated
|
||||||
|
Foreign Currency Translation Adjustments
|
$
|
(547.5
|
)
|
|
$
|
72.8
|
|
|
$
|
(474.7
|
)
|
|
Accumulated Other Comprehensive Loss
|
(547.8
|
)
|
|
72.8
|
|
|
(475.0
|
)
|
|||
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Net sales
|
$
|
823.8
|
|
|
$
|
534.8
|
|
|
Cost of sales
|
467.8
|
|
|
327.7
|
|
||
|
Gross profit
|
356.0
|
|
|
207.1
|
|
||
|
Selling, technical, general and administrative
|
284.0
|
|
|
192.0
|
|
||
|
Research and development
|
19.9
|
|
|
12.9
|
|
||
|
Operating profit
|
52.1
|
|
|
2.2
|
|
||
|
Interest, net
|
(93.8
|
)
|
|
(39.4
|
)
|
||
|
Other (expense) income
|
(74.3
|
)
|
|
35.6
|
|
||
|
Income tax expense
|
(18.4
|
)
|
|
(24.7
|
)
|
||
|
Net loss
|
$
|
(134.4
|
)
|
|
$
|
(26.3
|
)
|
|
|
Three Months Ended March 31,
|
||
|
(amounts in millions)
|
2016
|
||
|
Net sales
|
$
|
252.4
|
|
|
Cost of sales
|
164.4
|
|
|
|
Gross profit
|
88.0
|
|
|
|
Selling, technical, general and administrative
|
70.7
|
|
|
|
Research and development
|
7.0
|
|
|
|
Operating profit
|
10.3
|
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Net sales
|
$
|
823.8
|
|
|
$
|
534.8
|
|
|
|
Three Months Ended March 31, 2016
|
||
|
(amounts in millions)
|
$ Change
|
||
|
Change, adjusted for acquisitions and foreign currency translation
|
$
|
76.3
|
|
|
- Acquisitions
|
252.4
|
|
|
|
- Foreign Currency Translation
|
(39.7
|
)
|
|
|
Total Change
|
$
|
289.0
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Cost of sales
|
$
|
467.8
|
|
|
$
|
327.7
|
|
|
|
Three Months Ended March 31, 2016
|
||
|
(amounts in millions)
|
$ Change
|
||
|
Change, adjusted for acquisitions and foreign currency translation
|
$
|
(2.8
|
)
|
|
- Acquisitions
|
164.4
|
|
|
|
- Foreign Currency Translation
|
(21.5
|
)
|
|
|
Total Change
|
$
|
140.1
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Gross profit
|
$
|
356.0
|
|
|
$
|
207.1
|
|
|
|
Three Months Ended March 31, 2016
|
||
|
(amounts in millions)
|
$ Change
|
||
|
Change, adjusted for acquisitions and foreign currency translation
|
$
|
79.1
|
|
|
- Acquisitions
|
88.0
|
|
|
|
- Foreign Currency Translation
|
(18.2
|
)
|
|
|
Total Change
|
$
|
148.9
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Selling, technical, general and administrative
|
$
|
284.0
|
|
|
$
|
192.0
|
|
|
|
Three Months Ended March 31, 2016
|
||
|
(amounts in millions)
|
$ Change
|
||
|
Change, adjusted for acquisitions and foreign currency translation
|
$
|
34.0
|
|
|
- Acquisitions
|
70.7
|
|
|
|
- Foreign Currency Translation
|
(12.7
|
)
|
|
|
Total Change
|
$
|
92.0
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Research and development
|
$
|
19.9
|
|
|
$
|
12.9
|
|
|
|
Three Months Ended March 31, 2016
|
||
|
(amounts in millions)
|
$ Change
|
||
|
Change, adjusted for acquisitions and foreign currency translation
|
$
|
0.7
|
|
|
- Acquisitions
|
7.0
|
|
|
|
- Foreign Currency Translation
|
(0.7
|
)
|
|
|
Total Change
|
$
|
7.0
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Operating profit
|
$
|
52.1
|
|
|
$
|
2.2
|
|
|
|
Three Months Ended March 31, 2016
|
||
|
(amounts in millions)
|
$ Change
|
||
|
Change, adjusted for acquisitions and foreign currency translation
|
$
|
44.3
|
|
|
- Acquisitions
|
10.3
|
|
|
|
- Foreign Currency Translation
|
(4.7
|
)
|
|
|
Total Change
|
$
|
49.9
|
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Interest expense, net
|
$
|
(93.8
|
)
|
|
$
|
(39.4
|
)
|
|
Loss on derivative contracts
|
(5.3
|
)
|
|
—
|
|
||
|
Foreign exchange (loss) gain
|
(71.1
|
)
|
|
33.9
|
|
||
|
Other income, net
|
$
|
2.1
|
|
|
$
|
1.7
|
|
|
Total other expense
|
$
|
(168.1
|
)
|
|
$
|
(3.8
|
)
|
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
Income tax expense
|
$
|
(18.4
|
)
|
|
$
|
(24.7
|
)
|
|
Effective tax rate
|
(15.9
|
)%
|
|
(1,547
|
)%
|
||
|
|
Three Months Ended March 31,
|
||||||
|
(amounts in millions)
|
2016
|
|
2015
|
||||
|
|
|
|
(as restated
(1)
)
|
||||
|
Cash and cash equivalents, beginning of the period
|
$
|
432.2
|
|
|
$
|
397.3
|
|
|
Cash (used in) provided by operating activities
|
(210.4
|
)
|
|
2.8
|
|
||
|
Cash used in investing activities
|
(19.9
|
)
|
|
(2,291.1
|
)
|
||
|
Cash provided by financing activities
|
120.7
|
|
|
2,198.9
|
|
||
|
Exchange rate impact on cash and cash equivalents
|
7.1
|
|
|
(10.6
|
)
|
||
|
Cash and cash equivalents, end of the period
|
$
|
329.7
|
|
|
$
|
297.3
|
|
|
•
|
started the implementation of a global consolidation and planning system, which is expected to be completed during the later half of 2016;
|
|
•
|
implemented control processes as it relates to newly-acquired businesses and non-routine transactions;
|
|
•
|
implemented enhanced monitoring controls relating to the financial reporting and performance of Platform's newly-acquired businesses;
|
|
•
|
completed the implementation of a global tax reporting system;
|
|
•
|
enhanced Platform's financial planning and analysis function within its businesses and at the corporate level;
|
|
•
|
added further qualified resources to Platform's corporate and segment staff;
|
|
•
|
enhanced the controllership function in Platform's newly-acquired businesses; and
|
|
•
|
continued its recruiting efforts to hire qualified personnel.
|
|
•
|
quarterly variations in our operating results;
|
|
•
|
changes in the market’s expectations about our operating results;
|
|
•
|
our operating results failing to meet the expectation of management, securities analysts or investors in a particular period;
|
|
•
|
the failure to remediate identified material weaknesses;
|
|
•
|
changes in financial estimates and recommendations by securities analysts concerning our Company or our industry in general;
|
|
•
|
operating and securities price performance of companies that investors deem comparable to us;
|
|
•
|
news reports and publication of research reports relating to our business or trends in our markets;
|
|
•
|
changes in laws and regulations affecting our businesses;
|
|
•
|
announcements or strategic developments, acquisitions and other material events by us or our competitors;
|
|
•
|
sales of substantial amounts of common stock by our directors, executive officers or significant stockholders or the perception that such sales could occur;
|
|
•
|
adverse market reaction to any additional debt we incur in the future;
|
|
•
|
litigation and class action proceedings;
|
|
•
|
the failure to identify and complete acquisitions in the future or unexpected difficulties or developments related to the integration of recently completed, pending or future acquisitions;
|
|
•
|
actions by institutional stockholders;
|
|
•
|
general economic and political conditions such as recessions and acts of war or terrorism; and
|
|
•
|
other matters discussed in this Quarterly Report.
|
|
Exhibit
Number
|
Description
|
|
3.1(a)
|
Certificate of Incorporation (filed as Exhibit 3.1 of Post-Effective Amendment No.1 to the Registration Statement on Form S-4 (File No. 333-192778) filed on January 24, 2014, and incorporated herein by reference)
|
|
3.1(b)
|
Certificate of Amendment of Certificate of Incorporation (filed as Exhibit 3.1 of Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference)
|
|
3.1(c)
|
Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 of Current Report on Form 8-K filed on February 17, 2015, and incorporated herein by reference)
|
|
3.2
|
Amended and Restated By-laws (filed as Exhibit 3.2 of the Annual Report on Form 10-K filed on March 31, 2014, and incorporated herein by reference)
|
|
10.1
|
Form of Restricted Stock Unit Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Exhibit 10.11 to Platform’s Registration Statement on Form S-4 filed on January 2, 2014, and incorporated herein by reference)
|
|
10.2
|
Form of Performance-Based Restricted Stock Unit Award Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Exhibit 10.2 of Current Report on Form 8-K filed on March 25, 2016, and incorporated herein by reference)
|
|
10.3
|
Form of Non-Qualified Stock Option Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Exhibit 10.3 of Current Report on Form 8-K filed on March 25, 2016, and incorporated herein by reference)
|
|
10.4
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Appendix A to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference)
|
|
10.5
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan (filed as Appendix B to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference)
|
|
10.6*
|
Severance Agreement by and between Scot R. Benson and MacDermid, dated June 6, 2013
|
|
10.7
|
Form of Change in Control Agreement (filed as Exhibit 10.1 of Current Report on Form 8-K filed on April 8, 2016, and incorporated herein by reference)
|
|
31.1*
|
Principal Executive Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2*
|
Principal Financial Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1**
|
Principal Executive Officer and Principal Financial Officer Certifications Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101. INS*
|
XBRL Instance Document
|
|
101.SCH*
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL*
|
XBRL Extension Calculation Linkbase Document
|
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
PLATFORM SPECIALTY PRODUCTS CORPORATION
|
|
|
|
|
|
|
|
By:
|
/s/ Robert L. Worshek
|
|
|
|
Name: Robert L. Worshek
|
|
|
|
Title: Vice President and Chief Accounting Officer
(Principal Accounting Officer)
|
|
Exhibit
Number
|
Description
|
|
3.1(a)
|
Certificate of Incorporation (filed as Exhibit 3.1 of Post-Effective Amendment No.1 to the Registration Statement on Form S-4 (File No. 333-192778) filed on January 24, 2014, and incorporated herein by reference)
|
|
3.1(b)
|
Certificate of Amendment of Certificate of Incorporation (filed as Exhibit 3.1 of Current Report on Form 8-K filed on June 13, 2014, and incorporated herein by reference)
|
|
3.1(c)
|
Certificate of Designation of Series B Convertible Preferred Stock (filed as Exhibit 3.1 of Current Report on Form 8-K filed on February 17, 2015, and incorporated herein by reference)
|
|
3.2
|
Amended and Restated By-laws (filed as Exhibit 3.2 of the Annual Report on Form 10-K filed on March 31, 2014, and incorporated herein by reference)
|
|
10.1
|
Form of Restricted Stock Unit Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Exhibit 10.11 to Platform’s Registration Statement on Form S-4 filed on January 2, 2014, and incorporated herein by reference)
|
|
10.2
|
Form of Performance-Based Restricted Stock Unit Award Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Exhibit 10.2 of Current Report on Form 8-K filed on March 25, 2016, and incorporated herein by reference)
|
|
10.3
|
Form of Non-Qualified Stock Option Agreement – Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Exhibit 10.3 of Current Report on Form 8-K filed on March 25, 2016, and incorporated herein by reference)
|
|
10.4
|
Platform Specialty Products Corporation Amended and Restated 2013 Incentive Compensation Plan (filed as Appendix A to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference)
|
|
10.5
|
Platform Specialty Products Corporation 2014 Employee Stock Purchase Plan (filed as Appendix B to Platform’s Definitive Proxy Statement, as filed on April 25, 2014, and incorporated herein by reference)
|
|
10.6*
|
Severance Agreement by and between Scot R. Benson and MacDermid, dated June 6, 2013
|
|
10.7
|
Form of Change in Control Agreement (filed as Exhibit 10.1 of Current Report on Form 8-K filed on April 8, 2016, and incorporated herein by reference)
|
|
31.1*
|
Principal Executive Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2*
|
Principal Financial Officer Certification Pursuant to Exchange Act Rules 13a-14 and 15d-14 as adopted pursuant to the Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1**
|
Principal Executive Officer and Principal Financial Officer Certifications Pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101. INS*
|
XBRL Instance Document
|
|
101.SCH*
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL*
|
XBRL Extension Calculation Linkbase Document
|
|
101.DEF*
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB*
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE*
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|